TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01032083
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with citalopram will be initiated at 20mg/day for the first 4 weeks (or one placebo capsule), followed by the option to increase the dose to 40mg per day (or two placebo capsules) for the remainder of the study period.
Study: NCT03483194
Drug: Kalinox
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usually take care of by a gas mixture composed of 50% Nitrous Oxide, 50% Oxygen for the medical procedure (osteo-medullary biopsy)
Study: NCT00934050
Drug: ELND005 (scyllo-inositol)
Normalized name: Inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prior to 15Dec2009: ELND005 2000 mg PO BID for 48 weeks~After 15Dec2009: ELND005 250 mg PO BID for 48 weeks
Study: NCT00875550
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rescue medication for pain based on UMSS scores
Study: NCT00328926
Drug: Luveris® 75 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant human luteinizing hormone (r-hLH, lutropin alfa, Luveris®), 75 IU will be administered subcutaneously once daily. Duration of treatment cycle will be up to 14 days, or maximum of 21 days (if follicular maturation is imminent, based upon follicular growth and estradiol \[E2\] levels). Total duration will be of 3 treatment cycles.
Study: NCT00328926
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered subcutaneously once daily. Duration of treatment cycle will be up to 14 days, or maximum of 21 days (if follicular maturation is imminent, based upon follicular growth and E2 levels). Total duration will be of 3 treatment cycles.
Study: NCT02388971
Drug: MLN1202
Approvals — FDA: no, EMA: no, PMDA: no
Description: MLN1202 solution
Study: NCT02388971
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: MLN1202 placebo-matching solution
Study: NCT02695797
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IVIG (400mg/kg/day for 5 days) with oral prednisolone (60mg for 5days, than decrease by 10 mg every 2 day)
Study: NCT02828358
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02828358
Drug: Hydrocortisone Sodium Succinate
Normalized name: Hydrocortisone Sodium Succinate
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IT
Study: NCT02828358
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO, IV
Study: NCT02828358
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO, IV
Study: NCT02828358
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO, NG
Study: NCT02828358
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT, IV, PO
Study: NCT02828358
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO, NG
Study: NCT02330380
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will receive Methotrexate as detailed in the Group description.
Study: NCT02628236
Drug: Aminolevulinic Acid (ALA)
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light
Study: NCT02281643
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200mg oral doxycycline will be administered immediately (early) in the experimental arm or delayed in the comparator arm
Study: NCT00983177
Drug: lactose
Normalized name: Lactose
DrugBank: Lactose (DB04465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: lactose capsules twice daily
Study: NCT02987985
Drug: Acetaminophen, gabapentin
Approvals — FDA: no, EMA: no, PMDA: no
Description: acetaminophen 15 mg/kg, gabapentin 10 mg/kg
Study: NCT02987985
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: acetaminophen 15 mg/kg
Study: NCT02987985
Drug: Fentanyl, Dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 0.5 mcg/kg, Dexmedetomidine 0.3 mcg/kg
Study: NCT02987985
Drug: Sevoflurane, Fentanyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevoflurane (dose titrated to effect), Fentanyl as needed (dose at anesthesiologist's discretion)
Study: NCT05088343
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single oral dose of rosuvastatin on Day 1 or co-administered with hetrombopag on Day 11.
Study: NCT00040391
Drug: Investigational drug
Normalized name: INVESTIGATIONAL DRUGS FOR DEMENTIA
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00040391
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03025945
Drug: Nepafenac 0.3%
Normalized name: NEPAFENAC 0.3% OPH SUSP
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00829075
Drug: r-FSH
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00829075
Drug: HP-hMG
Normalized name: HP 502
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00829075
Drug: r-FSH plus HP-hMG
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02361502
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02257372
Drug: UMEC DPI
Normalized name: Umecta
Approvals — FDA: no, EMA: no, PMDA: no
Description: The UMEC DPI will contain one blister strip which will have 30 blisters of UMEC as dry powder blended with lactose and magnesium stearate, with no companion strip. Each actuation of the DPI will deliver the contents of one blister from each strip simultaneously.
Study: NCT02257372
Drug: Placebo DPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: The matching placebo DPI, identical in appearance to the inhaler containing active study medication, will have two blister strips, each containing 30 blisters of lactose and magnesium stearate.
Study: NCT02257372
Drug: ICS/LABA medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will use ICS/LABA combinations that are approved for the treatment of COPD at approved doses and frequency including SERETIDE 500/50mcg twice daily, FSC 500/50 mcg twice daily generic products such as AIRFLUSAL FORSPIRO inhaler 500/50mcg twice daily or ROLENIUM ELPENHALER inhaler 500/50mcg twice daily and SYMBICORT TURBUHALER inhaler at doses of 200/6mcg twice daily and 400/12mcg twice daily. The ICS/LABA will be sourced from local commercial stock while on the study
Study: NCT00003535
Drug: Antineoplaston therapy (Atengenal + Astugenal)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children with a recurrent/progressive high grade glioma will receive Antineoplaston therapy (Atengenal + Astugenal).
Study: NCT03860753
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pill capsules will look same as that of active drug.
Study: NCT04136873
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching CVL-231
Study: NCT01702987
Drug: statin
Normalized name: Statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: statin was given for 1 month to 21 patients
Study: NCT03113240
Drug: Glutamin
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteral Glutamine 0.3g/kg/day powdered glutamine to be mixed in with water and given via nasogastric tube q4 hrs.
Study: NCT01397370
Drug: GLPG0492
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution
Study: NCT01397370
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution
Study: NCT03115177
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The treatment group will receive 100mg of doxycycline IV in addition to cefazolin within 1 hour of incision for total shoulder arthroplasty.
Study: NCT02086747
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml iv, 4 times a day for 72 hours
Study: NCT02086747
Drug: Isotonic
Normalized name: Isotonic solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml iv, 4 times a day for 72 hours
Study: NCT00111800
Drug: DEN 30 mg
Normalized name: adenosine monophosphate Injectable Solution [My-O-Den]
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEN 30 mg capsules which were white, opaque capsules with no identifying markings, containing white to off-white beads.
Study: NCT00111800
Drug: DEN 45 mg
Normalized name: adenosine monophosphate Injectable Solution [My-O-Den]
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEN 45 mg capsules which were white, opaque capsules with no identifying markings, containing white to off-white beads.
Study: NCT00428909
Drug: Imatinib/Acetaminophen
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02634853
Drug: Placebo Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle Ophthalmic Solution
Study: NCT00004694
Drug: heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00318630
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will also receive placebo oral tablet.
Study: NCT02288195
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 825 mg/m² twice daily administered orally and concurrently with radiation therapy for 5 days per week.~1000 mg/m² po twice daily on days 1- 14 repeated every 21 days in Group A and adjuvant chemotherapy in Group B.
Study: NCT03924869
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT02401503
Drug: ABT-199
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction: Cycle 2: d1-7: 20mg, d8-14: 50mg, d15-21: 100mg, d22-28: 200mg; Cycle 3-6: d1-28: 400mg Maintenance: Cycles 1-8 (Duration 12 weeks): d1-84: 400mg
Study: NCT01961349
Drug: ICI35,868 (Diprivan)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treated by Anaesthesiologist
Study: NCT01961349
Drug: ICI35,868 (Diprivan) + EES0000645/A (SDS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treated by Endoscopist with EES0000645/A(SDS)
Study: NCT00717405
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: As prescribed
Study: NCT01843842
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safety and Efficiency of liquid dosage form
Study: NCT01236690
Drug: Cinobufacin injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinobufacin by Perfusion of Hepatic Artery Combining the Arterial Embolotherapy
Study: NCT02953340
Drug: SPI-2012
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplied in prefilled single-use syringes for subcutaneous injection, administered on Day 2 of each cycle
Study: NCT02953340
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600mg/m\^2 IV infusion administered on Day 1 of each cycle
Study: NCT02757105
Drug: BEKINDA
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02757105
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03282162
Drug: intranasal placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: An identical amount of intranasal administration of placebo will be assigned to each subject.
Study: NCT02385500
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For each phase of the study, the participants will receive a total of 84 placebo pills. The study medication will be provided by Pfizer.~For blinded distribution, each bottle of medications will be labeled with a random number for identification. The participant will indicate in a journal the dose taken each day.~The study participants will be monitored every 2 weeks with phone calls to assess tolerance or side-effects to the medication.
Study: NCT02126917
Drug: HC-ER + 40% Alcohol
Approvals — FDA: no, EMA: no, PMDA: no
Description: HC-ER 50 mg + 240 mL solution of 40% alcohol/orange juice in fasted state
Study: NCT02942914
Drug: LY3209590
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT02942914
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT02126917
Drug: HC-ER + 20% Alcohol
Approvals — FDA: no, EMA: no, PMDA: no
Description: HC-ER 50 mg + 240 mL solution of 20% alcohol/orange juice in fasted state
Study: NCT02126917
Drug: HC-ER + 0% Alcohol
Approvals — FDA: no, EMA: no, PMDA: no
Description: HC-ER 50 mg + 240 mL solution of 0% alcohol/orange juice in fasted state
Study: NCT03600480
Drug: NNC0174-0833
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive increasing dose levels of 0.16 mg, 0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg or 4.5 mg of NNC0174-0833 (subcutaneous \[s.c.\], in a lifted fold of the abdominal skin) injection once weekly starting with a very low dose and then escalated every 4 weeks to a slightly higher dose each time. Each participant will only be given one dose level.
Study: NCT03600480
Drug: Placebo (NNC0174-0833)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive once weekly injections of NNC0174-0833 matched placebo.
Study: NCT02168634
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1cc normal saline, local injection
Study: NCT03426722
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 500mg TID(PO)
Study: NCT04165772
Drug: capecitabine or 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 825mg/m2 BID concurrently with radiation per standard radiation guidelines. If patient is unable to tolerate oral medication, infusional 5-FU is an acceptable alternative.
Study: NCT01152840
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAD001 10 mg po daily medication~* Treatments will be continued until any of the following events occur:~  * progression of disease,~ * the subject develops unacceptable toxicity,~ * consent to participate in the study is withdrawn.
Study: NCT01854463
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: elemental calcium 200mg per day per 24 weeks
Study: NCT00001535
Drug: Syngeneic Lymphocytes (CD4+) Cultured with OKT3 (Ortho) and Interleukin-2 (Chiro
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02249585
Drug: Deep neuromuscular blockade
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anesthesia induction with rocuronium 0.8mg/kg → maintenance with rocuronium 0.3mg/kg to maintain PTC 1-2 twitch
Study: NCT03502395
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: A standardized equal volume of intravenous bolus dose of normal saline was given as loading dose then normal saline was administered on an equal rate of infusion.
Study: NCT00753558
Drug: Arm #1 :Oral solution and buccal gel of gentamicin and polymyxin E. Arm #2: Placebo.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm #1: Oral gentamicin \& polymyxin E, gentamicin \& polymyxin E buccal gel.~Arm #2: Oral placebo solutions, placebo buccal gel.
Study: NCT02761512
Drug: CJ-12420 50 mg QD
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CJ-12420 50 mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose gastric ulcer is not endoscopically healed(S1 or S2 stage) at Week 4, subjects will receive additional 4 weeks treatment of CJ-12420 50 mg.
Study: NCT02761512
Drug: CJ-12420 100 mg QD
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CJ-12420 100 mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose gastric ulcer is not endoscopically healed(S1 or S2 stage) at Week 4, subjects will receive additional 4 weeks treatment of CJ-12420 100 mg.
Study: NCT00614250
Drug: AVE0657
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules once a day at bedtime
Study: NCT00614250
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules once a day at bedtime
Study: NCT00006451
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00006451
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02840695
Drug: bDMARD treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with bDMARD includes registered ATC-codes: L04AA and L04AB.
Study: NCT04560738
Drug: [14C]-CC-92480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT03528343
Drug: Non-narcotic pain control
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education to use tylenol and motrin only for pain control unless this is unable to control pain. Rescue prescription provided.
Study: NCT00496730
Drug: simvastatin (+) ezetimibe
Normalized name: ezetimibe / simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: simvastatin (+) ezetimibe 10/20 mg ; tablet, once daily, 8 Weeks
Study: NCT03782402
Drug: Cannabinoids
Normalized name: cannabinoids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabinoids with THC and CBD versus placebo cannabinoids
Study: NCT02317861
Drug: RDEA3170
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Treatment
Study: NCT00761007
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet matching the three dose levels of ibodutant, once daily
Study: NCT03220542
Drug: Probiotics
Normalized name: probiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saccharomyces boulardii
Study: NCT03220542
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin
Study: NCT03548935
Drug: Placebo (semaglutide)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive semaglutide matching placebo s.c. injection(s) once-weekly as well as diet and physical activity counselling for 68 weeks.
Study: NCT01432873
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Placebo Oral placebo 1 Tab bid from day -6/-7 until discharge
Study: NCT04596007
Drug: HEC83518 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each dose of HEC83518 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.
Study: NCT04596007
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01594515
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for oral administration
Study: NCT04472585
Drug: Zinc
Normalized name: Zinc
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc Sulphate 20mg 3 times a day
Study: NCT04472585
Drug: Placebo empty capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo empty capsule
Study: NCT02833012
Drug: AC-1202
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 g AC-1202 (shaken in 180 mL of water) at Hour 0 on Day 1
Study: NCT02833012
Drug: Axona
Normalized name: AXONA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g Axona (shaken in 120 mL of water) at Hour 0 on Day 1
Study: NCT00296062
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Phase I: oral capecitabine twice daily on days 1-7 and 15-21.Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of capecitabine (during both odd- and even-numbered courses) until the maximum tolerated dose (MTD) is determined.Phase II:receive capecitabine (at the MTD determined in phase I(odd-numbered courses)
Study: NCT02009462
Drug: Artefill dermal filler
Normalized name: Dermal-Soothe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four treatment visits will be scheduled at baseline and at weeks 4, 12, and 24. Each treatment session will utilize no more than 8 mL of Artefill and no more than 30 syringes of Artefill.
Study: NCT04315181
Drug: Opioid Agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abuse liability evaluation.
Study: NCT04315181
Drug: Sedatives
Normalized name: SEDATIVES/HYPONTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abuse liability evaluation.
Study: NCT00679510
Drug: rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: tablet 10 mgs once daily
Study: NCT00679510
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01518972
Drug: Placebo medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Form: Placebo will be taken orally, in the form of pills.~Dosing: 9 AM, 3 PM, 9 PM~Days 1-2: 0 mg, 0 mg, 1 mg~Days 3-4: 1 mg, 1 mg, 1 mg~Days 5-7: 2 mg, 2 mg, 2 mg~Day 8-10: 2 mg, 2 mg, 6 mg~Day 11-14: 4 mg, 4 mg, 6 mg~Day 15-84: 4 mg, 4 mg, 8 mg
Study: NCT01529502
Drug: Inhaled Nitric Oxide (iNO) administration
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will breath iNO (80ppm) for 10 minutes before, during and for one hour after the autologous old-blood transfusion.
Study: NCT01218464
Drug: Conventional plus MSC treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received conventional treatment and taken i.v., once per 4 week, at a dose of 0.5\*10E6 MSC/kg body for 12 weeks.
Study: NCT01218464
Drug: Conventional plus pacebo treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 12 weeks.
Study: NCT00510172
Drug: Prostacyclin, PGI2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ng/kg/min of epoprostenol (stable PGI2)
Study: NCT04196075
Drug: Andrographis Paniculata
Normalized name: Andrographis paniculata
Approvals — FDA: no, EMA: no, PMDA: no
Description: AP as palliative treatment
Study: NCT03546283
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients with hypertensive intracerebral hemorrhage will be randomized into giving placebos, the other treatments in this group follow the guidelines on the treatment of hypertensive intracerebral hemorrhage.